These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 22492316)
1. Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis. Tazawa H; Yano S; Yoshida R; Yamasaki Y; Sasaki T; Hashimoto Y; Kuroda S; Ouchi M; Onishi T; Uno F; Kagawa S; Urata Y; Fujiwara T Int J Cancer; 2012 Dec; 131(12):2939-50. PubMed ID: 22492316 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. Tazawa H; Kagawa S; Fujiwara T Acta Med Okayama; 2013; 67(6):333-42. PubMed ID: 24356717 [TBL] [Abstract][Full Text] [Related]
3. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model. Wang H; Wei F; Li H; Ji X; Li S; Chen X Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955 [TBL] [Abstract][Full Text] [Related]
4. Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer. Tazawa H; Kuroda S; Hasei J; Kagawa S; Fujiwara T Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28698504 [TBL] [Abstract][Full Text] [Related]
5. Oncolytic adenoviruses for the treatment of brain tumors. Gomez-Manzano C; Fueyo J Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384 [TBL] [Abstract][Full Text] [Related]
6. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768 [TBL] [Abstract][Full Text] [Related]
7. E2F1 regulates autophagy and the transcription of autophagy genes. Polager S; Ofir M; Ginsberg D Oncogene; 2008 Aug; 27(35):4860-4. PubMed ID: 18408756 [TBL] [Abstract][Full Text] [Related]
8. C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Klein SR; Piya S; Lu Z; Xia Y; Alonso MM; White EJ; Wei J; Gomez-Manzano C; Jiang H; Fueyo J Oncogene; 2015 Oct; 34(41):5295-301. PubMed ID: 25619840 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Lee KH; Chen YL; Yeh SD; Hsiao M; Lin JT; Goan YG; Lu PJ Oncogene; 2009 Sep; 28(38):3360-70. PubMed ID: 19597470 [TBL] [Abstract][Full Text] [Related]
10. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740 [TBL] [Abstract][Full Text] [Related]
12. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205 [TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells. Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040 [TBL] [Abstract][Full Text] [Related]
14. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Sugio K; Sakurai F; Katayama K; Tashiro K; Matsui H; Kawabata K; Kawase A; Iwaki M; Hayakawa T; Fujiwara T; Mizuguchi H Clin Cancer Res; 2011 May; 17(9):2807-18. PubMed ID: 21346145 [TBL] [Abstract][Full Text] [Related]
15. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895 [TBL] [Abstract][Full Text] [Related]
16. EGFR signaling inhibits E2F1-induced apoptosis in vivo: implications for cancer therapy. Ginsberg D Sci STKE; 2007 Jan; 2007(371):pe4. PubMed ID: 17264315 [TBL] [Abstract][Full Text] [Related]
17. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. Geoerger B; van Beusechem VW; Opolon P; Morizet J; Laudani L; Lecluse Y; Barrois M; Idema S; Grill J; Gerritsen WR; Vassal G J Gene Med; 2005 May; 7(5):584-94. PubMed ID: 15651070 [TBL] [Abstract][Full Text] [Related]
18. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob. Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547 [TBL] [Abstract][Full Text] [Related]
19. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Xie J; Chen M; Zhou J; Mo MS; Zhu LH; Liu YP; Gui QJ; Zhang L; Li GQ Oncol Rep; 2014 Apr; 31(4):1715-22. PubMed ID: 24573489 [TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. Sasaki T; Tazawa H; Hasei J; Kunisada T; Yoshida A; Hashimoto Y; Yano S; Yoshida R; Uno F; Kagawa S; Morimoto Y; Urata Y; Ozaki T; Fujiwara T Clin Cancer Res; 2011 Apr; 17(7):1828-38. PubMed ID: 21325287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]